-
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating Pancreatic Cancer patients with certain genetic mutations.
Category: News
-
How Microsatellite Instability Works in Colorectal Cancer
Understanding one’s biomarkers, such as microsatellite stable (MSS) or instable (MSI) status in tumors, is key in understanding how a patient with colorectal cancer may be treated.
Category: News
-
Helping Caregivers: Advice, Support and More
At the GI Cancer Patient Summit, a panel of caregivers drew upon personal experience to offer advice and discuss what more can be done for individuals in this role of the cancer journey.
Category: News
-
Marshall Details Treatment Options for Patients With GI Cancers in 2 Case Studies
John Marshall, MD, recently shared the treatment considerations and decisions he makes when treating patients with gastrointestinal (GI) cancers
Category: News
-
Immunotherapy Hype and Oncologists’ Fear of Failure Drive ‘Hail Mary’ Treatments
John Marshall speaks with Leonard Saltz and Tanios Bekaii-Saab about the destructive trend of trying experimental drugs before having the data, and the new ‘right to try’ law.
Category: News
-
Underuse of exon mutational analysis for gastrointestinal stromal tumors
Increased use of EMA will improve clinical outcomes in both current and future patients by informing treatment plans and identifying new, potential therapeutic targets as the role of genetics in medicine continues to expand.
Category: News
-
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive malignancy with the lowest 5-year survival rate of all cancers in part owing to the lack of tumor-specific therapy and the rapid metastatic nature of this cancer.
Category: News
-
Expert Highlights Long-Lasting Benefits of Pembrolizumab for Patients With GI Cancers
Pembrolizumab (Keytruda), for example, has induced durable responses in certain subsets of patients with gastric and colorectal cancer (CRC), but many patients still do not respond to this type of therapy.
Category: News
-
Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers
Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.
Category: News
-
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
TML-high rate varied widely among gastrointestinal cancers. Although MSI is conceivably the main driver for TML-high, other factors may be involved.
Category: News